Clinically validated products of good level efficacy, into an over prescribed US / global market of addictive benzos and opiates with debilitating side effects.....
those same clinically validated products have no pier in the US due to the FDA ban on such trials being conducted with medicinal cannabis and the like....no time frame on that changing....yet this product can address that market almost immediatley in 34/35 US states....HELLO ???
The release of the secondary outpoint results around the end of March ...and those results potentially indicating a substantial improvement measured against the deficiencies of the current prescribed drugs and therapies ( which richard described as 'big issues around existing therapies') is an unmatched development for this company....or any company for that matter....soon to be released into revenue stream in the US and straight into markets in Aust, NZ, Germany and the UK.
impatient for the secondary outpoints data now.....bring on 31st March.
Wake me up...I must be dreaming.....hahahaha -
All in my IMO
GLATHAS
Ann: Zelira Meets Primary Endpoints for Insomnia Trial, page-151
Add ZLD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
70.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.943M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 808 | 68.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 70.0¢ | 1508 | 1 |
View Market Depth
| Last trade - 10.09am 11/09/2024 (20 minute delay) ? |
| ZLD (ASX) Chart |
Day chart unavailable